214 related articles for article (PubMed ID: 31567203)
21. Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma.
Sneddon S; Leon JS; Dick IM; Cadby G; Olsen N; Brims F; Allcock RJ; Moses EK; Melton PE; de Klerk N; Musk AW; Robinson BW; Creaney J
Gene; 2015 May; 563(1):103-5. PubMed ID: 25796603
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
Rusch A; Ziltener G; Nackaerts K; Weder W; Stahel RA; Felley-Bosco E
Lung Cancer; 2015 Jan; 87(1):77-9. PubMed ID: 25468148
[TBL] [Abstract][Full Text] [Related]
23. Malignant Peritoneal Mesothelioma in an Adolescent Male With BAP1 Deletion.
Taylor S; Carpentieri D; Williams J; Acosta J; Southard R
J Pediatr Hematol Oncol; 2015 Jul; 37(5):e323-7. PubMed ID: 25222065
[TBL] [Abstract][Full Text] [Related]
24. Molecular pathogenesis of malignant mesothelioma.
Sekido Y
Carcinogenesis; 2013 Jul; 34(7):1413-9. PubMed ID: 23677068
[TBL] [Abstract][Full Text] [Related]
25. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guo G; Chmielecki J; Goparaju C; Heguy A; Dolgalev I; Carbone M; Seepo S; Meyerson M; Pass HI
Cancer Res; 2015 Jan; 75(2):264-9. PubMed ID: 25488749
[TBL] [Abstract][Full Text] [Related]
26. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
Chen-Yost HI; Tjota MY; Gao G; Mitchell O; Kindler H; Segal J; Husain AN; Mueller J; Schulte JJ
Am J Clin Pathol; 2023 Sep; 160(3):238-246. PubMed ID: 37141416
[TBL] [Abstract][Full Text] [Related]
27. Risk of second primary cancers after malignant mesothelioma and vice versa.
Chen T; Kharazmi E; Lou J; Zhang X; Sundquist K; Hemminki K
Cancer Lett; 2016 Aug; 379(1):94-9. PubMed ID: 27260871
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
[TBL] [Abstract][Full Text] [Related]
29. Malignant Mesothelioma and Its Non-Asbestos Causes.
Attanoos RL; Churg A; Galateau-Salle F; Gibbs AR; Roggli VL
Arch Pathol Lab Med; 2018 Jun; 142(6):753-760. PubMed ID: 29480760
[TBL] [Abstract][Full Text] [Related]
30. [Malignant mesothelioma and constitutional BAP1 gene mutations].
Neviere Z; Berthet P; Polycarpe F; Dubos-Arvis C; Dô P; Gervais R
Rev Mal Respir; 2019 Feb; 36(2):241-248. PubMed ID: 30686559
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.
Zauderer MG; Jayakumaran G; DuBoff M; Zhang L; Francis JH; Abramson DH; Cercek A; Nash GM; Shoushtari A; Chapman P; D'Angelo S; Arnold AG; Siegel B; Fleischut MH; Ni A; Rimner A; Rusch VW; Adusumilli PS; Travis W; Sauter JL; Zehir A; Mandelker D; Ladanyi M; Robson M
J Thorac Oncol; 2019 Nov; 14(11):1989-1994. PubMed ID: 31323388
[TBL] [Abstract][Full Text] [Related]
32. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
Althakfi W; Gazzo S; Blanchet M; Isaac S; Piaton E; Villeneuve L; Glehen O; Gilly FN; Brevet M
Cytopathology; 2020 Jan; 31(1):5-11. PubMed ID: 31713897
[TBL] [Abstract][Full Text] [Related]
33. Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation.
Ribeiro C; Campelos S; Moura CS; Machado JC; Justino A; Parente B
Ann Oncol; 2013 Aug; 24(8):2147-50. PubMed ID: 23585512
[TBL] [Abstract][Full Text] [Related]
34. Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a BAP1 mutation.
Lee J; Turetsky J; Nasri E; Rogers SC
BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38142057
[TBL] [Abstract][Full Text] [Related]
35. Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
Ohar JA; Cheung M; Talarchek J; Howard SE; Howard TD; Hesdorffer M; Peng H; Rauscher FJ; Testa JR
Cancer Res; 2016 Jan; 76(2):206-15. PubMed ID: 26719535
[TBL] [Abstract][Full Text] [Related]
36. Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations.
Wiesner T; Fried I; Ulz P; Stacher E; Popper H; Murali R; Kutzner H; Lax S; Smolle-Jüttner F; Geigl JB; Speicher MR
J Clin Oncol; 2012 Nov; 30(32):e337-40. PubMed ID: 23032617
[No Abstract] [Full Text] [Related]
37. Biallelic germline and somatic mutations in malignant mesothelioma: multiple mutations in transcription regulators including mSWI/SNF genes.
Yoshikawa Y; Sato A; Tsujimura T; Otsuki T; Fukuoka K; Hasegawa S; Nakano T; Hashimoto-Tamaoki T
Int J Cancer; 2015 Feb; 136(3):560-71. PubMed ID: 24916674
[TBL] [Abstract][Full Text] [Related]
38. Co-occurring Mutations of Tumor Suppressor Genes,
Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
[No Abstract] [Full Text] [Related]
39. Establishment and characterization of CRISPR/Cas9-mediated NF2
Wahiduzzaman M; Karnan S; Ota A; Hanamura I; Murakami H; Inoko A; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y
Cancer Sci; 2019 Jan; 110(1):180-193. PubMed ID: 30417500
[TBL] [Abstract][Full Text] [Related]
40. Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.
Xu J; Kadariya Y; Cheung M; Pei J; Talarchek J; Sementino E; Tan Y; Menges CW; Cai KQ; Litwin S; Peng H; Karar J; Rauscher FJ; Testa JR
Cancer Res; 2014 Aug; 74(16):4388-97. PubMed ID: 24928783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
